“…Currently, in the market, it is available in four different formulations: Jardiance (empagliflozin, 10 mg/25 mg tablets), Glyxambi (empagliflozin and linagliptin, 10/5 mg or 25/5 mg tablets), Synjardy (empagliflozin and metformin, film-coated tablets: 5 mg or 12.5 mg/1000 mg, and 5 mg/850 mg) and Synjardy XR (empagliflozin and metformin extended-release, 12.5 mg/1000 mg tablets). 42 An early discovery patent (WO2006117359, 2006) describing the synthesis of empagliflozin (5) is discussed in Scheme 20. 43 The synthesis involves a total of eight steps with an overall yield of 8% and commences from commercially available 2-chloro-5-bromobenzoic acid (26c), which was treated with oxalyl chloride to generate in situ the acid chloride 26c′.…”